Broadcom secures a landmark agreement to supply OpenAI with custom AI accelerators, marking a strategic pivot to become a core silicon partner for hyperscalers and deepening its integration into the global AI build-out.
Applied Optoelectronics (AAOI) is positioning itself at the forefront of the AI infrastructure build-out, securing a significant 800G transceiver order from a hyperscale customer and expanding its Texas manufacturing footprint. While these moves signal strong revenue momentum, they also amplify existing concerns over customer concentration and profitability.
Cullen/Frost Bankers (NYSE: CFR) reported robust fourth-quarter results, beating analyst estimates on earnings and revenue. The Texas-based regional bank also announced a new $300 million share repurchase program and raised its guidance, fueling a debate on whether its current valuation fully reflects its growth trajectory.
Honeywell International posts a robust Q4 with record orders and backlog, while announcing an accelerated timeline to spin off its core Aerospace business as a standalone public company by late 2026, a move set to redefine its investment profile.
Silver prices plunged by a record 30% in a single session after President Trump nominated former Fed Governor Kevin Warsh to lead the central bank, a move seen as tempering expectations for aggressive rate cuts and bolstering the dollar.
Footwear giant Deckers Brands posted quarterly revenue and profit that handily beat Wall Street estimates, driven by surging global demand for its HOKA and UGG labels. The company raised its full-year outlook, citing robust direct-to-consumer growth and international momentum.
Citizens JMP reaffirms its bullish stance on Salesforce, citing the explosive growth of its AI platform Agentforce and strong enterprise adoption as key catalysts for sustained outperformance.
Insurance broker Arthur J. Gallagher raises its quarterly dividend, rewarding shareholders even as it continues to pursue an active mergers and acquisitions pipeline, signaling confidence in its dual strategy of capital returns and growth.
The ASX-listed miner's heavily discounted rights issue aims to shore up its balance sheet after a period of steep losses, but analysts are divided on whether the fresh capital marks a new beginning or merely delays deeper challenges.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
Shares of Deckers Outdoor surged over 17% Friday after the footwear and apparel company reported robust Q3 earnings, driven by full-price selling across its UGG and HOKA brands and prompting an upward revision to its annual forecast.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.
Analyst firm Clear Street has raised its price target for Critical Metals Corp. (CRML) to $20, citing a strategic joint venture with a Saudi industrial group to build a rare earth processing facility. The move aims to diversify supply chains away from China and support Western defense needs.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.
